Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Corvus Pharmaceuticals ( (CRVS) ) has issued an update.
On January 20, 2026, Corvus Pharmaceuticals reported positive data from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in patients with moderate to severe atopic dermatitis, showing that an extended 8-week regimen produced deeper clinical responses and a favorable safety profile consistent with earlier cohorts. In cohort 4, 75% of soquelitinib-treated patients achieved EASI 75 and 25% reached EASI 90, versus 20% and 0% on placebo, with a 72% mean EASI reduction at day 56 compared with 40% for placebo, sustained disease control into follow-up, and meaningful activity even in patients previously treated with or resistant to dupilumab and JAK inhibitors; biomarker data suggested immune-system rebalancing via ITK inhibition, and the company indicated that these results support advancing soquelitinib into a Phase 2 trial in atopic dermatitis in the first quarter of 2026, potentially strengthening its competitive positioning in oral therapies for difficult-to-treat eczema.
The most recent analyst rating on (CRVS) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Corvus Pharmaceuticals stock, see the CRVS Stock Forecast page.
Spark’s Take on CRVS Stock
According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue with ongoing losses and material cash burn). The latest earnings call provides support via improved quarterly loss trends, a cash runway into Q4 2026, and meaningful clinical trial progress, but near-term technical momentum is soft and valuation is constrained by negative earnings.
To see Spark’s full report on CRVS stock, click here.
More about Corvus Pharmaceuticals
Corvus Pharmaceuticals, based in South San Francisco and listed on Nasdaq, is a clinical-stage biopharmaceutical company developing immunology-focused therapies, including the oral ITK inhibitor soquelitinib, for inflammatory and immune-mediated diseases such as atopic dermatitis, with an emphasis on patients who have failed existing systemic treatments.
Average Trading Volume: 1,344,680
Technical Sentiment Signal: Buy
Current Market Cap: $601.2M
Learn more about CRVS stock on TipRanks’ Stock Analysis page.